以“全球R&BD集团”为目标 Intron Bio 正在为 (1) 人类受试者和 (2) 疾病治疗药物开发新药。 (3)以First-in-Class(MoA_based)的方向和目标, 以成为不局限于单纯的研究,以业务发展为目标的“全球R&BD集团”为目标, 以及不断投资建设多个新的生物制药管道, 我们正在逐步将(L/O)技术转移到国内外市场,用于各种新药管道。 通过这种方式,我们将逐步提升我们作为一家新型生物制药公司的价值。 Aiming for "Global R&BD Group" Intron Bio is developing new drugs for (1) human subjects and (2) disease treatment drugs. (3) With the direction and goal of First-in-Class (MoA_based), Aiming to become a “global R&BD group” that is not limited to simple research but aims for business development, As well as continuously investing in building a number of new biopharmaceutical pipelines, We are gradually transferring (L/O) technology to domestic and overseas markets for various new drug pipelines. Through this, we will gradually increase our value as a new biopharmaceutical company.